SAN FRANCISCO - Hepatitis C treatment is in a strange space right now. The approval earlier this year of the first two direct-acting antiviral drugs, Incivek (telaprevir, Vertex Pharmaceuticals Inc.) and Victrelis (boceprevir, Merck & Co. Inc.) has brought new options to hepatitis C patients.The approval of telaprevir and boceprevir has already prompted the American Association for the Study of Liver Diseases to release new treatment guidelines for hepatitis C.